The Global Drug Development organization oversees the clinical development of new medicines that early research indicates may be safe and effective.
The Innovative Medicines Division has two business units:
Novartis Pharmaceuticals commercializes innovative, patented primary care and specialty medicines to enhance health outcomes for patients and health-care providers.
Novartis Oncology commercializes a portfolio of patented oncology, hematology and rare disease medicines to address the medical needs of people with cancer and related diseases. In oncology we are a leader in driving the practice of precision oncology treatment. Precision oncology is the evolving understanding of how cancers develop on a genomic level and our ability to develop drugs that hone in on those targets – ultimately leading to better patient outcomes.
Sandoz is a global leader in generic pharmaceuticals and biosimilars that pioneers novel approaches to help people around the world access high-quality medicines. Sandoz has a portfolio of more than 1,000 products covering all major therapeutic areas.